Cycloheximide

Catalog No.S7418 Batch:S741803

Technical Data

Formula	C₁₅H₂₃NO₄
Molecular Weight	281.35	CAS No.	66-81-9
Solubility (25°C)*	In vitro	DMSO	56 mg/mL (199.04 mM)
		Ethanol	56 mg/mL (199.04 mM)
		Water	15 mg/mL (53.31 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	Cycloheximide, an antifungal antibiotic, is an eukaryote protein synthesis inhibitor with IC50 of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively. Cycloheximide suppresses ferroptosis and inhibits autophagy.Solutions are unstable and should be fresh-prepared.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.
In vitro	Cyclohexamide, a protein synthesis inhibitor, reduces GSIV-induced host cell death by attenuating phosphatidylserine exposure and loss of ΔΨm from apoptosis/necrosis.^[1]
In vivo	Cycloheximide, a protein synthesis inhibitors, acts on memory by altering modulators of memory formation as a secondary consequence of the inhibition of protein synthesis.^[2]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines grouper fin cell line (GF-1) Concentrations 0.33 µg/ml Incubation Time 0-5 days Method Monolayers of GF-1 cells (4.0 mL, 10⁵ cells/mL) on 60-mm Petri dishes are cultivated for at least 20 h, rinsed twice with phosphate buffered saline (PBS), treated with the protein synthesis inhibitor cycloheximide (CHX, 0.33 µg/mL) and ANT inhibitor BKA (20 µM) for 0 5 days, then infected with GSIV K1 strain (multiplicity of infection [m.o.i. ] = 5) for 0 5 days post-infection (dpi). At the end of the incubation period, each sample is removed from the medium and washed with PBS. Cells are then incubated for 10-15 min with 100 µL staining solution.
Animal Study:^{^[2]}	Animal Models Male ICR mice Dosages 30mg/kg, 60mg/kg,120 mg/kg Administration i.p.

Cell Assay:^{^[1]}

Cell lines
grouper fin cell line (GF-1)
Concentrations
0.33 µg/ml
Incubation Time
0-5 days
Method
Monolayers of GF-1 cells (4.0 mL, 10⁵ cells/mL) on 60-mm Petri dishes are cultivated for at least 20 h, rinsed twice with phosphate buffered saline (PBS), treated with the protein synthesis inhibitor cycloheximide (CHX, 0.33 µg/mL) and ANT inhibitor BKA (20 µM) for 0 5 days, then infected with GSIV K1 strain (multiplicity of infection [m.o.i. ] = 5) for 0 5 days post-infection (dpi). At the end of the incubation period, each sample is removed from the medium and washed with PBS. Cells are then incubated for 10-15 min with 100 µL staining solution.

Animal Study:^{^[2]}

Animal Models
Male ICR mice
Dosages
30mg/kg, 60mg/kg,120 mg/kg
Administration
i.p.

References

[4] Santos DA, et al. Nucleic Acids Res. 2019;47(10):4974-4985.

+ Expand

Selleck's Cycloheximide has been cited by 288 publications

Engineered a dual-targeting HA-TPP/A nanoparticle for combination therapy against KRAS-TP53 co-mutation in gastrointestinal cancers [ Bioact Mater, 2024, 32:277-291]	PubMed: 37876556
EFHD2 suppresses intestinal inflammation by blocking intestinal epithelial cell TNFR1 internalization and cell death [ Nat Commun, 2024, 15(1):1282]	PubMed: 38346956
Activation of hepatic adenosine A1 receptor ameliorates MASH via inhibiting SREBPs maturation [ Cell Rep Med, 2024, 5(3):101477]	PubMed: 38508143
Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma [ Exp Mol Med, 2024, 56(1):177-191]	PubMed: 38177295
Heterogeneous ferroptosis susceptibility of macrophages caused by focal iron overload exacerbates rheumatoid arthritis [ Redox Biol, 2024, 69:103008]	PubMed: 38142586
5-HT7R enhances neuroimmune resilience and alleviates meningitis by promoting CCR5 ubiquitination [ J Adv Res, 2024, S2090-1232(24)00079-1]	PubMed: 38432392
Diallyl disulfide induces DNA damage and growth inhibition in colorectal cancer cells by promoting POU2F1 ubiquitination [ Int J Biol Sci, 2024, 20(4):1125-1141]	PubMed: 38385081
Hsa_circ_0007990 promotes breast cancer growth via inhibiting YBX1 protein degradation to activate E2F1 transcription [ Cell Death Dis, 2024, 15(2):153]	PubMed: 38378679
Musashi-2 potentiates colorectal cancer immune infiltration by regulating the post-translational modifications of HMGB1 to promote DCs maturation and migration [ Cell Commun Signal, 2024, 22(1):117]	PubMed: 38347600
BOP1 contributes to the activation of autophagy in polycystic ovary syndrome via nucleolar stress response [ Cell Mol Life Sci, 2024, 81(1):101]	PubMed: 38409361

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.